Frank Davis is a notable inventor based in El Cerrito, CA (US). He has made significant contributions to the field of biochemistry, particularly in the development of chemically modified hemoglobin. With a total of 2 patents, his work focuses on enhancing the properties of hemoglobin for medical applications.

Latest Patents

Davis's latest patents include innovations related to chemically modified hemoglobin. One of his key inventions is a method for producing chemically modified hemoglobin that is effective, stable, and non-immunogenic. This invention involves a novel and efficient process where stroma-free hemoglobin is first deoxygenated and reduced. It is then conjugated with a polyalkylene oxide, such as polyethylene glycol (PEG), under conditions that maintain the structural integrity of the heme oxygen binding site. The use of cysteine in an inert atmosphere during deoxygenation and reduction is a specific aspect of this method. The resulting PEG-modified hemoglobin compounds exhibit superior oxygen transport capabilities, extended half-life, and low immunogenicity.

Career Highlights

Frank Davis has had a distinguished career, working with Enzon, Inc., where he has been able to apply his innovative ideas in a practical setting. His work has contributed to advancements in medical treatments and therapies, particularly in the area of oxygen transport in the body.

Collaborations

Davis has collaborated with notable colleagues, including Kwang Nho and Shmuel Zalipsky. These partnerships have further enhanced the research and development of his patented technologies.

Conclusion

Frank Davis is a pioneering inventor whose work in chemically modified hemoglobin has the potential to revolutionize medical treatments. His innovative approaches and collaborations continue to push the boundaries of biochemistry and medicine.